EuroBiotech: More Articles of Note

(Image: NS Newsflash/CC BY 2.0)

> CureVac unveiled leadership changes. Ingmar Hoerr is set to transition to the chairman role, leaving the CEO seat free for Daniel Menichella. Release

> InflaRx netted $57.1 million in a stock offering. The financing sets InflaRx up to run midphase trials of antihuman C5a monoclonal antibody IFX-1. Statement 

> Memo Therapeutics raised CHF 5 million ($5 million) to advance its antibody candidates. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Motif Bio hired Stephanie Noviello, M.D., to support its filing for approval of iclaprim in Europe. Noviello joins the antibiotic drug developer from Bristol-Myers Squibb. Statement (PDF) 

> French authorities cleared Advicenne to start a phase 2/3 trial of its lead candidate in cystinuria, a rare inherited disease that causes recurrent kidney stone formation. Release  

> Lundbeck gave up trying to fix a manufacturing problem that has stymied commercialization of Carnexiv. The FDA approved the seizure drug in 2016 but Lundbeck subsequently ran into a problem it has been unable to solve. Lundbeck is now looking to divest the asset. Statement (PDF)

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.